Posted by: Siddhesh Dhuri | July 16, 2013
Despite the many advantages of using social media, the pharmaceutical industry has been a laggard in embracing it. The primary reason for this has been the lack of FDA guidance on the use of this medium. In a survey of health and pharma executives, 78% cited regulatory concerns as a leading challenge in social media adoption, while 67% cited compliance issues. For 41% of the participants, Adverse Event (AE) reporting was the main issue.